• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Preventive Medicine: An International Journal Devoted to Practice and Theory >Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up.
【24h】

Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up.

机译：一项为期28年的随访TAMRISK研究中的血细胞比容和冠心病死亡风险。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To evaluate whether hematocrit (HCT) is associated with coronary heart disease (CHD) mortality in men over 55 years of age in Finland. METHODS: Health survey data were recorded in 1980 from 670 men, aged 55 years. The causes of deaths during a 28-year follow-up were obtained from official records. Statistical comparisons were done by Cox proportional hazard regression model after dividing the men into two groups, one with HCT<50% and the other, HCT> or =50%. RESULTS: There were altogether 412 deaths of all causes, including 140 from CHD. In men having HCT<50%, the crude CHD mortality rate per 10,000 population was 2203, while in men with HCT> or =50%, the corresponding figure was 4255. Men with HCT> or =50% were 2.4 times (95% CI 1.6-3.5) more likely to die from CHD than were men with HCT<50%. After adjusting for established coronary risk factors, the increased risk remained 1.8-fold (95 % CI, 1.1-2.7). CONCLUSIONS: Borderline polycythemia was associated with increased CHD mortality. The cut-off value in our study was > or =50%, proposing that for men over 55 years of age such HCT levels might be an additional risk factor.
机译：目的：评估芬兰55岁以上男性的血细胞比容（HCT）是否与冠心病（CHD）死亡率相关。方法：1980年对670名55岁的男性进行了健康调查。从官方记录中获得了28年随访期间的死亡原因。将男性分为两组，一组的HCT <50％，另一组的HCT>或= 50％，然后通过Cox比例风险回归模型进行统计学比较。结果：共有412例各种原因导致的死亡，包括140例冠心病死亡。在HCT <50％的男性中，每10,000人的CHD死亡率为2203，而在HCT>或= 50％的男性中，相应的数字为4255。HCT>或= 50％的男性为2.4倍（95％）。与HCT <50％的男性相比，CI 1.6-3.5）更有可能死于冠心病。在调整已确定的冠心病危险因素后，增加的风险仍然是1.8倍（95％CI，1.1-2.7）。结论：边界性红细胞增多症与冠心病死亡率增加有关。在我们的研究中，临界值大于或等于50％，这表明对于55岁以上的男性，此类HCT水平可能是另一个危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号